Derailing a disease: stem cells slow dogs' muscular dystrophy.Muscle-producing stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young injected into dogs with the equivalent of Duchenne muscular dystrophy Duchenne muscular dystrophy (DMD) The most severe form of muscular dystrophy, DMD usually affects young boys and causes progressive muscle weakness, usually beginning in the legs. significantly slowed the disease's progression, researchers report. In people who have the incurable disease, abbreviated as DMD (1) (Digital Micromirror Device) See DLP. (2) (Digital Multi-layer Disk) See high-def DVD formats. , muscles rapidly degenerate, and patients typically die in their late teens or early adulthood. Although steroid injections and other therapies can ease some of the disease's symptoms, no treatment slows DMD's progression. Ten years ago, Giulio Cossu of the San Raffaele San Raffaele may refer to:
Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. . When the researchers collected these cells from healthy mice and then injected the cells into mice carrying a genetic mutation Noun 1. genetic mutation - (genetics) any event that changes genetic structure; any alteration in the inherited nucleic acid sequence of the genotype of an organism chromosomal mutation, mutation that causes muscular dystrophy muscular dystrophy (dĭs`trōfē), any of several inherited diseases characterized by progressive wasting of the skeletal muscles. There are five main forms of the disease. , disease progression slowed, as measured in several tests. But because mice don't show the same symptoms as people do, the scientists needed to use a different animal to test whether stem cells might be effective against DMD in people. In new work, Cossu's team studied golden retrievers that had a natural canine version of the DMD-causing mutation. These animals experience rapid muscular degeneration similar to that in people with the disease. Six dogs received five monthly injections of stem cells from a healthy donor dog. The treatment started either at 1 month or 5 months of age, after symptoms had appeared. All these dogs received drugs to prevent tissue rejection. Four other dogs had their stem cells removed and the disease-causing gene replaced with a healthy one. Each dog then received its own, altered cells in five monthly injections starting at 4 months of age. With this strategy, the dogs didn't need antirejection an·ti·re·jec·tion adj. Preventing rejection of a transplanted tissue or organ. drugs. Cossu and his colleagues compared three untreated dogs with the animals receiving each of the stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. procedures. Though the disease affected each animal differently, by 8 months of age, untreated animals typically could no longer walk, and they all died a year or so after birth. The dogs that received healthy dogs' stem cells did much better. One of the three dogs that received donor cells 1 month after birth could still walk well at 13 months. Two of the three dogs given donor cells later in their lives were more mobile at 10 months of age than they had been when treatment started. Dogs that received their own cells with corrected genes also showed slower disease progression than did the untreated dogs but not as dramatic an improvement as did the dogs that received donor cells. Cossu says that the difference might relate to the gene put into the stem cells. Because the DMD-related gene is so long that it's difficult to get into cells, the researchers worked with a shortened form of the healthy gene. This truncated version might not offer all the benefits of a gene from a healthy donor dog. Cossu's team reports its results online for an upcoming issue of Nature. Jeffrey Chamberlain of the University of Washington in Seattle, who studies various forms of muscular dystrophy, warns that the research has a long way to go before yielding a treatment for people with DMD. Nevertheless, he calls the findings "a significant breakthrough." He says, "Any disease that involves significant muscle wasting could be a candidate for this approach." |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion